David Herrington to Estrogen Replacement Therapy
This is a "connection" page, showing publications David Herrington has written about Estrogen Replacement Therapy.
Connection Strength
3.692
-
Rossouw J, Bray P, Liu J, Kooperberg C, Hsia J, Lewis C, Cushman M, Bonds D, Hendrix S, Papanicolaou G, Howard T, Herrington D. Estrogen receptor polymorphisms and the vascular effects of hormone therapy. Arterioscler Thromb Vasc Biol. 2011 Feb; 31(2):464-9.
Score: 0.337
-
Yeboah J, Klein K, Brosnihan B, Reboussin D, Herrington DM. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease. Menopause. 2008 Nov-Dec; 15(6):1060-4.
Score: 0.292
-
Lakoski SG, Liu Y, Brosnihan KB, Herrington DM. Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study. Atherosclerosis. 2008 Mar; 197(1):443-7.
Score: 0.269
-
Yeboah J, Reboussin DM, Waters D, Kowalchuk G, Herrington DM. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J. 2007 Mar; 153(3):439-44.
Score: 0.260
-
Bray PF, Howard TD, Vittinghoff E, Sane DC, Herrington DM. Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood. 2007 Mar 01; 109(5):1862-9.
Score: 0.255
-
Lakoski SG, Brosnihan B, Herrington DM. Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial. Am Heart J. 2005 Nov; 150(5):907-11.
Score: 0.237
-
Seely EW, Brosnihan KB, Jeunemaitre X, Okamura K, Williams GH, Hollenberg NK, Herrington DM. Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women. Clin Endocrinol (Oxf). 2004 Mar; 60(3):315-21.
Score: 0.211
-
Herrington DM, Howard TD. ER-alpha variants and the cardiovascular effects of hormone replacement therapy. Pharmacogenomics. 2003 May; 4(3):269-77.
Score: 0.200
-
Herrington DM. Hormone replacement therapy and heart disease: replacing dogma with data. Circulation. 2003 Jan 07; 107(1):2-4.
Score: 0.195
-
Klein KP, Herrington DM. Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women. Medscape Womens Health. 2002 Sep-Oct; 7(5):2.
Score: 0.191
-
Herrington DM, Vittinghoff E, Lin F, Fong J, Harris F, Hunninghake D, Bittner V, Schrott HG, Blumenthal RS, Levy R. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 2002 Jun 25; 105(25):2962-7.
Score: 0.188
-
Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation. 2002 Apr 23; 105(16):1879-82.
Score: 0.186
-
Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, Meyers DA, Bleecker ER. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002 Mar 28; 346(13):967-74.
Score: 0.185
-
Lamon-Fava S, Herrington DM, Horvath KV, Schaefer EJ, Asztalos BF. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. Metabolism. 2010 Dec; 59(12):1794-800.
Score: 0.082
-
Puntawangkoon C, Morgan TM, Herrington DM, Hamilton CA, Hundley WG. Submaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin. Menopause. 2010 Jan-Feb; 17(1):114-20.
Score: 0.079
-
Lamon-Fava S, Herrington DM, Reboussin DM, Sherman M, Horvath K, Schaefer EJ, Asztalos BF. Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women. Atherosclerosis. 2009 Jul; 205(1):325-30.
Score: 0.074
-
Mellen PB, Cefalu WT, Herrington DM. Diabetes, the metabolic syndrome, and angiographic progression of coronary arterial disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 2006 Jan; 26(1):189-93.
Score: 0.059
-
Hu P, Greendale GA, Palla SL, Reboussin BA, Herrington DM, Barrett-Connor E, Reuben DB. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis. 2006 Apr; 185(2):347-52.
Score: 0.058
-
Nair GV, Waters D, Rogers W, Kowalchuk GJ, Stuckey TD, Herrington DM. Pulse pressure and coronary atherosclerosis progression in postmenopausal women. Hypertension. 2005 Jan; 45(1):53-7.
Score: 0.056
-
Herrington DM. Role of estrogen receptor-alpha in pharmacogenetics of estrogen action. Curr Opin Lipidol. 2003 Apr; 14(2):145-50.
Score: 0.050
-
Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003 Jan 07; 138(1):1-9.
Score: 0.049
-
Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002 Jul 03; 288(1):49-57.
Score: 0.047
-
Furberg CD, Vittinghoff E, Davidson M, Herrington DM, Simon JA, Wenger NK, Hulley S. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation. 2002 Feb 26; 105(8):917-22.
Score: 0.046
-
Imamura F, Jacques PF, Herrington DM, Dallal GE, Lichtenstein AH. Adherence to 2005 Dietary Guidelines for Americans is associated with a reduced progression of coronary artery atherosclerosis in women with established coronary artery disease. Am J Clin Nutr. 2009 Jul; 90(1):193-201.
Score: 0.019
-
Reuben DB, Palla SL, Hu P, Reboussin BA, Crandall C, Herrington DM, Barrett-Connor E, Greendale GA. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. Am J Med. 2006 Feb; 119(2):167.e1-8.
Score: 0.015
-
Nair GV, Chaput LA, Vittinghoff E, Herrington DM. Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease. Chest. 2005 May; 127(5):1498-506.
Score: 0.014
-
Varosy PD, Shlipak MG, Vittinghoff E, Black DM, Herrington D, Hulley SB, Browner WS. Fracture and the risk of coronary events in women with heart disease. Am J Med. 2003 Aug 15; 115(3):196-202.
Score: 0.013
-
Sherman AM, Shumaker SA, Kancler C, Zheng B, Reboussin DM, Legault C, Herrington DM. Baseline health-related quality of life in postmenopausal women with coronary heart disease: the Estrogen Replacement and Atherosclerosis (ERA) trial. J Womens Health (Larchmt). 2003 May; 12(4):351-62.
Score: 0.012
-
Byington RP, Furberg CD, Herrington DM, Herd JA, Hunninghake D, Lowery M, Riley W, Craven T, Chaput L, Ireland CC, Applegate WB. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol. 2002 Oct 01; 22(10):1692-7.
Score: 0.012